Pharmaceutical Resources
Executive Summary
Resumes marketing of metronidazole 250 mg and 500 mg. "This product represents a previously approved ANDA which was placed on hold by the company pending the completion of an external audit by the company's independent regulatory consultant," the company says Nov. 5. Pharmaceutical Resources' Par subsidiary was cleared by FDA Oct. 25 under the agency's applications integrity policy ('The Pink Sheet" Nov. 1, In Brief). The company announces that it "plans to reintroduce several previously approved products in fiscal 1994".